Search

FDA grants Lenire tinnitus treatment device De Novo approval

Neuromod Devices Ltd. is proud to announce that the US Food and Drug Administration (FDA) has granted De Novo approval to Lenire.

New patient education infographic from Cl-ear™

According to research into the nation’s hearing health habits commissioned by Cl-ear™, the fastest growing OTC ear care range¹, DIY ear wax removal is rife.

Leading in cochlear implant reliability

All MED-EL’S titanium cochlear implants since 2006 have an overall cumulative survival rate of over 99%.

Minimise waiting times with Peptest!

In laryngopharyngeal reflux (LPR), refluxed stomach contents travel up the oesophagus and reach the larynx, causing chronic extra-gastrointestinal symptoms such as a persistent cough, hoarseness or difficulty swallowing, meaning it is often attributed to ENT problems.

MED-EL revolutionises cochlear implantation with unparalleled synchrotron dataset of temporal bones

MED-EL, a leading innovator in the field of cochlear implant research and development, has announced an agreement with the Western University (London, Canada) and Mitacs to gain exclusive access to an extraordinary synchrotron dataset of temporal bones.

Peptest Q&A

Untreated reflux can cause inflammation, scarring, narrowing and precancerous changes in the oesophagus and larynx, and may increase the risk of asthma and sleep apnoea.

Neuromod Devices’ €30m funding powers Lenire expansion

Neuromod Devices, the global technology business behind scientifically proven tinnitus treatment technology, Lenire, closed €30m funding to expand availability of the groundbreaking tinnitus intervention.